MET and lung adenocarcinoma: MET exon 14 skipping mutations—which occur in approximately 3–4% of lung adenocarcinomas—are now effectively treated with MET tyrosine kinase inhibitors such as capmatinib, tepotinib, and savolitinib [98,99,100].